SAN JOSE, Calif., Aug. 9, 2024 /PRNewswire/ — Lykos Therapeutics ("Lykos"), a company dedicated to transforming mental healthcare, announced that the U.S. Food and Drug Administration ("FDA") has issued a complete response letter ("CRL") for the…Original Article
Lykos Therapeutics Announces Complete Response Letter for Midomafetamine Capsules for PTSD
